drugset / Trial / NCT05782959
Phase 1 Study of BCD-245 in Subjects With Neuroblastoma
Non-randomizedSequentialOpen-labelTreatment
Summary
The aim of the study is to investigate the safety, pharmacokinetics, pharmacodynamics, and immunogenicity of BCD-245 after its single and multiple intravenous infusions at escalating doses in subjects with relapsed/refractory neuroblastoma.
Timeline
- Start
- 2021-11-29
- Primary completion
- 2023-06
- Completion
- 2023-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BCD-245 | Monoclonal antibody | — | Intravenous |